Silas Inman
OncLive.com
Contact Silas
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Silas:
Elranatamab Shows Promise for Penta/Triple-Refractory Myeloma
Treatment with the CD3/BCMA bispecific antibody elranatamab elicited an objective response rate by blinded independent central review of 61.0% in patients with penta- or triple-class refractory multiple myeloma who had not received a prior BCMA-targeted therapy. → Read More
Frontline Dostarlimab Shows Superior PFS vs Pembrolizumab in NSCLC
Treatment with dostarlimab (Jemperli) plus chemotherapy reduced the risk of disease progression or death by 30% compared with pembrolizumab (Keytruda) plus chemotherapy as a frontline treatment for patients with metastatic non-squamous non–small cell lung cancer. → Read More
Rivoceranib Elicits Promising Responses in Adenoid Cystic Carcinoma
The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma. → Read More
Radiotherapy Unnecessary for Some Luminal A Breast Cancers
Radiotherapy can safely be omitted from treatment plans following breast conserving surgery without jeopardizing recurrence rates for patients aged 55 years and older who have low-grade, T1N0, luminal A breast cancer with a Ki67 expression of 13.25% or less, according to findings from the LUMINA study. → Read More
Trastuzumab Deruxtecan Is New Standard of Care for HER2-Low MBC
Treatment with fam-trastuzumab deruxtecan-nxki doubled progression-free survival and reduced the risk of death by 36% compared with physician's choice of chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer. → Read More
Adjuvant Everolimus Displays RFS Benefit in Very High-Risk RCC
Adjuvant everolimus significantly improved recurrence-free survival when compared with placebo in patients with very high-risk renal cell carcinoma. → Read More
Sugemalimab Shows Promise for Natural Killer/T-cell Lymphoma
Treatment with the anti–PD-L1 IgG4 antibody sugemalimab resulted in a response for nearly half of patients and a complete response in one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma. → Read More
Biomarkers Allow for Tailoring TNBC Treatments
Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine. → Read More
Pamrevlumab May Address Unmet Need for Locally Advanced Pancreatic Cancer
February 17, 2021 – Pamrevlumab, a first-in-class inhibitor of connective tissue growth factor activity, is being evaluated in combination with gemcitabine and nab-paclitaxel (Abraxane) in a phase 3 trial for patients with unresectable locally advanced pancreatic cancer, a population in need of new options. → Read More
Frontline Olaparib/Bevacizumab Maintenance Combo Extends PFS in Ovarian Cancer
Frontline maintenance therapy with the combination of olaparib and bevacizumab improved median progression-free survival versus bevacizumab and placebo for patients with newly diagnosed, advanced ovarian cancer. → Read More
Novel Research Methods Could Expedite New Drug Development
Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic. → Read More
New Therapies Intriguing for Elusive Targets in NSCLC
Two new therapies are showing encouraging findings for patients with NSCLC with either RET rearranged or EGFR exon 20 insertions, raising hope that 2 hard-to-target driver alterations may soon have an associated targeted treatment. → Read More
New Targeted Therapies Show Promise for METex14-Altered NSCLC
Two highly selective MET inhibitors, tepotinib and capmatinib showed promising clinical activity in the first- and second-line treatment of patients with MET exon 14-altered advanced non–small cell lung cancer. → Read More
Subcutaneous Daratumumab Shows Similar Efficacy, Greater Convenience in Phase III Myeloma Trial
A subcutaneous flat-dose version of daratumumab demonstrated noninferior efficacy with a reduction in the treatment burden compared with the original intravenous formulation of the anti-CD38 monoclonal antibody for patients with relapsed/refractory multiple myeloma. → Read More
Adjuvant Ipilimumab Shows Sustained Efficacy at 7 Years for Stage III Melanoma
Adjuvant ipilimumab elicited a 25% reduction in the risk of recurrence or death compared with placebo for patients with surgically resected high-risk, stage III melanoma. → Read More
Treatment Tailoring Possible With Gene Expression Profiling
Each gene expression-based test available for risk prediction in patients with breast cancer has unique properties and they are not interchangeable, placing importance on the clinical studies used to validate the clinical utility of each assay. → Read More
LOXO-292 Granted Breakthrough Therapy Designation for Lung and Thyroid Cancer
The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This destination will expedite the development and review of the drug. → Read More
FDA Updates Immunotherapy Labels for Bladder Cancer Treatment
The FDA has incorporated PD-L1 status into the labels for Keytruda (pembrolizumab) and Tecentriq (atezolizumab) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma, based on lower overall survival (OS) rates with the PD-1/PD-L1 inhibitors compared with platinum-based chemotherapy for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma. → Read More
Chemo Regimen Helps Control Locally Advanced Pancreatic Cancer
“Disease control is key in our patients with locally advanced disease, as it may lead to opportunities for additional treatment interventions, including radiotherapy, or even, in some favorable cases, surgical resection,” said lead study author Pascal Hammel, M.D., Ph.D. → Read More
Cabometyx Improves Survival in Patients With Advanced Hepatocellular Carcinoma
“Patients with advanced hepatocellular carcinoma often have a poor prognosis and limited treatment options following prior systemic therapy,” lead investigator Ghassan K. Abou-Alfa, M.D. → Read More